ThromboGenics to launch ocriplasmin in United States

ThromboGenics NV has confirmed January 14 for the U.S. launch of ocriplasmin intravitreal injection
(Jetrea) for the treatment of VMA.

Source: Modern Medicine - January 9, 2013 Category: Journals (General) Source Type: news